Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir

Filippo Canducci, Elisa R. Ceresola, Enzo Boeri, Vincenzo Spagnuolo, Francesca Cossarini, Antonella Castagna, Adriano Lazzarin, Massimo Clementi

Research output: Contribution to journalArticle


Novel integrase inhibitors are in advanced clinical development, and cross-resistance data are needed to consider the possibility to plan a sequential usage within this class of antiretroviral drugs. Ex vivo phenotypic assays were conducted on 11 wild-type and 27 fully replicating recombinant viruses obtained from 11 patients failing previous raltegravir-containing regimens. Dolutegravir maintained its activity in vitro on viruses with mutations in position 143 and 155. However, viruses with mutation Q148R associated with secondary mutations and the combination Q148H+G140S were instead associated with a reduced level of susceptibility to dolutegravir in vitro.

Original languageEnglish
Pages (from-to)1811-1815
Number of pages5
JournalJournal of Infectious Diseases
Issue number11
Publication statusPublished - Dec 1 2011


ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this